A recent meta-analysis, published in The BMJ and widely reported, confirms that individuals discontinuing weight-loss medications, particularly GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), experience significant and rapid weight regain. The study, involving data from 37 trials and over 9,000 participants, found that people who stopped these newer, highly effective drugs regained nearly 10 kilograms within a year. They were projected to return to their baseline weight within approximately 1.5 to 1.8 years. Crucially, the rate of weight regain after stopping medication was found to be approximately four times faster compared to individuals who lost weight through behavioral weight management programs focused on diet and exercise. The average monthly regain was 0.4 kg for all medications, increasing to 0.8 kg for GLP-1s, whereas behavioral programs saw a regain of about 0.1 kg per month. Beyond weight, the cardiometabolic benefits achieved during treatment, such as improved blood pressure, cholesterol levels, and HbA1c, also reverted to pre-treatment levels within about 1.4 years of medication cessation. Health experts and pharmacists emphasize that these findings underscore the need to view obesity as a chronic, relapsing condition requiring sustained, long-term management. Weight-loss medications, while highly effective, are not a standalone or short-term cure. They are most beneficial when integrated with comprehensive and sustained lifestyle changes, including a balanced diet and regular physical activity. This combined approach is vital not only for enhancing initial weight loss but, more importantly, for maintaining health benefits and preventing rebound weight gain after discontinuing medication. The World Health Organization (WHO) also recommends intensive behavioral interventions alongside GLP-1 therapies to enhance treatment outcomes.